On April 4, 2024 Medivir AB (Nasdaq Stockholm: MVIR) reported that the Annual Report for 2023 now is available at the company’s website: www.medivir.com (Press release, Medivir, APR 4, 2024, View Source [SID1234641801]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In the fall of 2023, very promising data from the ongoing phase 1b/2a study with Medivir’s spearhead project fostrox in combination with Lenvima were presented. The combination has shown continued improved clinical benefit in patients with advanced primary liver cancer (HCC) and at ASCO (Free ASCO Whitepaper)-GI in January 2024, data were presented showing further increases in the proportion of patients achieving a clinically relevant reduction in their liver tumor and patients staying on treatment longer with stopped tumor growth. This attracted very strong interest and the data has improved further in the first quarter of 2024.
The clear clinical benefit and great medical need present an opportunity to accelerate the clinical development of fostrox with the ambition of becoming the first approved pharmaceutical therapy for the second-line treatment of HCC, a market worth ~$2.5 billion annually. These efforts to bring fostrox closer to potentially accelerated approval are Medivir’s absolute focus in the continued clinical development. In addition to fostrox, which is carried out by the company, several of the projects that Medivir has licensed out to partners will also enter the clinical phase in 2024.
This and much more can be found in Medivir’s Annual Report 2023, published today at the website;